Six-compound combo remedy ameliorates corticosterone-induced depressive behaviors in mice via targeting 5-hydroxytryptamine receptor 1A signaling

Keyphrases

• Corticosterone 100%
• Depressive-like Behavior 100%
• 5-hydroxytryptamine Receptor 1A 100%
• Houpo 100%
• Microglia 60%
• Neurological Disorders 40%
• Active Compounds 40%
• Spontaneous Excitatory Postsynaptic Current (sEPSC) 40%
• BV2 Cells 40%
• BV2 Microglia 40%
• Dysregulation 20%
• Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) 20%
• Herbal Medicine 20%
• Interaction Network 20%
• Antidepressants 20%
• Network Pharmacology 20%
• Mouse Model 20%
• Baicalin 20%
• Active Target 20%
• Global Public Health 20%
• Innate Immunity 20%
• Enrichment Score 20%
• High Enrichment 20%
• Intraperitoneal Injection 20%
• Scutellarin 20%
• Luteolin 20%
• 6-shogaol 20%
• Public Health System 20%
• Medical Challenges 20%
• Roemerine 20%
• WAY-100635 20%
• Parallel Assay 20%
• N-nornuciferine 20%
• Differentiated PC12 Cells 20%
• Serotonergic Synapse 20%

Medicine and Dentistry

• Decoction 100%
• Corticosterone 100%
• Microglia 100%
• Serotonin 1A Receptor 100%
• Receptor 60%
• Serotonin 60%
• Nervous System Disorder 40%
• Public Health 20%
• Side Effect 20%
• Homeopathy 20%
• Baicalein 20%
• Intraperitoneal Drug Administration 20%
• Innate Immunity 20%
• Spectroscopy 20%
• PC12 Cell Line 20%
• Health System 20%
• Luteolin 20%
• Interaction Network 20%
• Shogaol 20%
• Synapse 20%
• Scutellarin 20%
• Antidepressant 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Corticosterone 100%
• Serotonin 1A Receptor 100%
• Receptor 75%
• Serotonin 75%
• Mouse Model 25%
• Side Effect 25%
• Network Pharmacology 25%
• Baicalein 25%
• Intraperitoneal Injection 25%
• Scutellarin 25%
• Luteolin 25%
• Shogaol 25%
• Antidepressant 25%